Clinical Trial Update: Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing genetic factors that influence response to cisplatin, vinblastine, and temozolomide in metastatic melanoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Temozolomide (Temozolomide)
• Vinblastine (vinblastine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma, Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-05-06